{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:37:07Z","timestamp":1791423427489,"version":"4.3.3"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1093\/jac\/dki248","type":"journal-article","created":{"date-parts":[[2005,7,22]],"date-time":"2005-07-22T20:13:58Z","timestamp":1122063238000},"page":"470-480","source":"Crossref","is-referenced-by-count":284,"title":["Tigecycline"],"prefix":"10.1093","volume":"56","author":[{"given":"George A.","family":"Pankey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,7,22]]},"reference":[{"key":"key\n\t\t\t\t20171012164821_B1","unstructured":"Shlaes DM, Projan SJ, Edwards JE. Antibiotic discovery: state of the state. ASM News2004; 70:275\u201381."},{"key":"key\n\t\t\t\t20171012164821_B2","unstructured":"Bush K. Why it is important to continue antibacterial drug discovery. ASM News2004; 70:282\u20137."},{"key":"key\n\t\t\t\t20171012164821_B3","doi-asserted-by":"crossref","unstructured":"Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis2004; 38:1279\u201386.","DOI":"10.1086\/420937"},{"key":"key\n\t\t\t\t20171012164821_B4","unstructured":"Infectious Diseases Society of America. Bad Bugs, No Drugs as Antibiotic Discovery Stagnates \u2026 A Public Health Crisis Brews, July 2004. http:\/\/www.idsociety.org (September 2004, date last accessed)."},{"key":"key\n\t\t\t\t20171012164821_B5","doi-asserted-by":"crossref","unstructured":"Ehrhardt AF, Russo R. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections. Am J Med2001; 111 Suppl 9A: 30S\u20138S.","DOI":"10.1016\/S0002-9343(01)01029-4"},{"key":"key\n\t\t\t\t20171012164821_B6","doi-asserted-by":"crossref","unstructured":"Buckingham SC, McDougal LK, Cathey LD et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr Infect Dis J2004; 23:619\u201324.","DOI":"10.1097\/01.inf.0000131981.67342.c4"},{"key":"key\n\t\t\t\t20171012164821_B7","doi-asserted-by":"crossref","unstructured":"Charlebois ED, Perdreau-Remington F, Kreiswirth B et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis2004; 39:47\u201354.","DOI":"10.1086\/421090"},{"key":"key\n\t\t\t\t20171012164821_B8","doi-asserted-by":"crossref","unstructured":"Cazzola M, Blasi F, Centanni S et al. Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections. Pulm Pharmacol Ther2001; 14:367\u201381.","DOI":"10.1006\/pupt.2001.0302"},{"key":"key\n\t\t\t\t20171012164821_B9","doi-asserted-by":"crossref","unstructured":"Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest2001; 119:397S\u2013404S.","DOI":"10.1378\/chest.119.2_suppl.397S"},{"key":"key\n\t\t\t\t20171012164821_B10","doi-asserted-by":"crossref","unstructured":"Johnson AP, Livermore DM, Tillotson GS. Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated? J Hosp Infect2001; 49 Suppl A: S3\u201311.","DOI":"10.1016\/S0195-6701(01)90029-5"},{"key":"key\n\t\t\t\t20171012164821_B11","doi-asserted-by":"crossref","unstructured":"Kang C-I, Kim S-H, Park WB et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis2004; 39:812\u20138.","DOI":"10.1086\/423382"},{"key":"key\n\t\t\t\t20171012164821_B12","doi-asserted-by":"crossref","unstructured":"Melzer M, Eykyn SJ, Gransden WR et al. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis2003; 37:1453\u201360.","DOI":"10.1086\/379321"},{"key":"key\n\t\t\t\t20171012164821_B13","doi-asserted-by":"crossref","unstructured":"Bouchillon SK, Johnson BM, Hobana DJ et al. Determining incidence of extended spectrum \u03b2-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001\u20132002. Int J Antimicrob Agents2004; 24:119\u201324.","DOI":"10.1016\/j.ijantimicag.2004.01.010"},{"key":"key\n\t\t\t\t20171012164821_B14","doi-asserted-by":"crossref","unstructured":"Hiramatsu K, Okuma K, Ma XX et al. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis2002; 15:407\u201313.","DOI":"10.1097\/00001432-200208000-00009"},{"key":"key\n\t\t\t\t20171012164821_B15","doi-asserted-by":"crossref","unstructured":"Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis2001; 1:147\u201355.","DOI":"10.1016\/S1473-3099(01)00091-3"},{"key":"key\n\t\t\t\t20171012164821_B16","doi-asserted-by":"crossref","unstructured":"Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev2001; 65:232\u201360.","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"key\n\t\t\t\t20171012164821_B17","doi-asserted-by":"crossref","unstructured":"Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des1998; 4:119\u201332.","DOI":"10.2174\/138161280401221007113202"},{"key":"key\n\t\t\t\t20171012164821_B18","doi-asserted-by":"crossref","unstructured":"Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum \u03b2-lactamases. Diagn Microbiol Infect Dis2001; 40:173\u20137.","DOI":"10.1016\/S0732-8893(01)00269-3"},{"key":"key\n\t\t\t\t20171012164821_B19","doi-asserted-by":"crossref","unstructured":"Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect2000; 6:159\u201363.","DOI":"10.1046\/j.1469-0691.2000.00034-6.x"},{"key":"key\n\t\t\t\t20171012164821_B20","unstructured":"Jones R, Fritsche T, Sader H et al. Antimicrobial activity of tigecycline (GAR-936) tested against Enterobacteriaceae, and selected non-fermentative Gram-negative bacilli, a worldwide sample. Abstract P939. Clin Microbiol Infect2004; 10 Suppl 3: 247."},{"key":"key\n\t\t\t\t20171012164821_B21","doi-asserted-by":"crossref","unstructured":"Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis2000; 36:19\u201336.","DOI":"10.1016\/S0732-8893(99)00092-9"},{"key":"key\n\t\t\t\t20171012164821_B22","doi-asserted-by":"crossref","unstructured":"Jones RN. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn Microbiol Infect Dis1999; 35:249\u201352.","DOI":"10.1016\/S0732-8893(99)00090-5"},{"key":"key\n\t\t\t\t20171012164821_B23","doi-asserted-by":"crossref","unstructured":"Bauer G, Berens C, Projan SJ et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother2004; 53:592\u20139.","DOI":"10.1093\/jac\/dkh125"},{"key":"key\n\t\t\t\t20171012164821_B24","doi-asserted-by":"crossref","unstructured":"Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol2001; 1:464\u20139.","DOI":"10.1016\/S1471-4892(01)00081-9"},{"key":"key\n\t\t\t\t20171012164821_B25","doi-asserted-by":"crossref","unstructured":"Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs2004; 64:63\u201388.","DOI":"10.2165\/00003495-200464010-00005"},{"key":"key\n\t\t\t\t20171012164821_B26","doi-asserted-by":"crossref","unstructured":"Postier RG, Green SL, Klein SR et al. Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther2004; 26:704\u201314.","DOI":"10.1016\/S0149-2918(04)90070-7"},{"key":"key\n\t\t\t\t20171012164821_B27","unstructured":"Murray J, Wilson S, Klein S et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract L-739, p. 416. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B28","doi-asserted-by":"crossref","unstructured":"Connell SR, Tracz DM, Nierhaus KH et al. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother2003; 47:3675\u201381.","DOI":"10.1128\/AAC.47.12.3675-3681.2003"},{"key":"key\n\t\t\t\t20171012164821_B29","doi-asserted-by":"crossref","unstructured":"Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother1999; 43:738\u201344.","DOI":"10.1128\/AAC.43.4.738"},{"key":"key\n\t\t\t\t20171012164821_B30","doi-asserted-by":"crossref","unstructured":"Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy2000; 20:219S\u201328S.","DOI":"10.1592\/phco.20.14.219S.35046"},{"key":"key\n\t\t\t\t20171012164821_B31","doi-asserted-by":"crossref","unstructured":"Hirata T, Saito A, Nishino K et al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother2004; 48:2179\u201384.","DOI":"10.1128\/AAC.48.6.2179-2184.2004"},{"key":"key\n\t\t\t\t20171012164821_B32","unstructured":"Ruzin A, Keeney D, Visalli MA et al. AcrAB efflux-mediated decreased susceptibility to tigecycline in Enterobacter spp. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract 1061, p. 81. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B33","doi-asserted-by":"crossref","unstructured":"Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist2000; 6:277\u201382.","DOI":"10.1089\/mdr.2000.6.277"},{"key":"key\n\t\t\t\t20171012164821_B34","doi-asserted-by":"crossref","unstructured":"Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother2004; 48:4479\u201381.","DOI":"10.1128\/AAC.48.11.4479-4481.2004"},{"key":"key\n\t\t\t\t20171012164821_B35","doi-asserted-by":"crossref","unstructured":"Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother2003; 47:400\u20134.","DOI":"10.1128\/AAC.47.1.400-404.2003"},{"key":"key\n\t\t\t\t20171012164821_B36","doi-asserted-by":"crossref","unstructured":"Betriu C, Rodriguez-Avial I, Sanchez BA et al; Spanish Group of Tigecycline. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother2002; 46:892\u20135.","DOI":"10.1128\/AAC.46.3.892-895.2002"},{"key":"key\n\t\t\t\t20171012164821_B37","doi-asserted-by":"crossref","unstructured":"Goldstein EJ, Citron DM, Merriam CV et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother2000; 44:2747\u201351.","DOI":"10.1128\/AAC.44.10.2747-2751.2000"},{"key":"key\n\t\t\t\t20171012164821_B38","doi-asserted-by":"crossref","unstructured":"Cercenado E, Cercenado S, Gomez JA et al. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides (letter). J Antimicrob Chemother2003; 52:138\u20139.","DOI":"10.1093\/jac\/dkg289"},{"key":"key\n\t\t\t\t20171012164821_B39","doi-asserted-by":"crossref","unstructured":"Low DE, Kreiswirth BN, Weiss K et al. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int J Antimicrob Agents2002; 20:220\u20132.","DOI":"10.1016\/S0924-8579(02)00132-2"},{"key":"key\n\t\t\t\t20171012164821_B40","doi-asserted-by":"crossref","unstructured":"Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob Agents Chemother2000; 44:2225\u20139.","DOI":"10.1128\/AAC.44.8.2225-2229.2000"},{"key":"key\n\t\t\t\t20171012164821_B41","doi-asserted-by":"crossref","unstructured":"Kitzis MD, Ly A, Goldstein FW. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae (letter). Antimicrob Agents Chemother2004; 48:366\u20137.","DOI":"10.1128\/AAC.48.1.366-367.2004"},{"key":"key\n\t\t\t\t20171012164821_B42","doi-asserted-by":"crossref","unstructured":"Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother2000; 44:1085\u20138.","DOI":"10.1128\/AAC.44.4.1085-1088.2000"},{"key":"key\n\t\t\t\t20171012164821_B43","doi-asserted-by":"crossref","unstructured":"Betriu C, Culebras E, Rodriguez-Avial I et al. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother2004; 48:323\u20135.","DOI":"10.1128\/AAC.48.1.323-325.2004"},{"key":"key\n\t\t\t\t20171012164821_B44","doi-asserted-by":"crossref","unstructured":"Patel R, Rouse MS, Piper KE et al. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis2000; 38:177\u20139.","DOI":"10.1016\/S0732-8893(00)00193-0"},{"key":"key\n\t\t\t\t20171012164821_B45","doi-asserted-by":"crossref","unstructured":"Bozdogan B, Esel D, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother2003; 52:864\u20138.","DOI":"10.1093\/jac\/dkg457"},{"key":"key\n\t\t\t\t20171012164821_B46","doi-asserted-by":"crossref","unstructured":"van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother2000; 44:943\u20139.","DOI":"10.1128\/AAC.44.4.943-949.2000"},{"key":"key\n\t\t\t\t20171012164821_B47","doi-asserted-by":"crossref","unstructured":"Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamido- minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents2001; 18:29\u201335.","DOI":"10.1016\/S0924-8579(01)00355-7"},{"key":"key\n\t\t\t\t20171012164821_B48","doi-asserted-by":"crossref","unstructured":"Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother2002; 49:479\u201387.","DOI":"10.1093\/jac\/49.3.479"},{"key":"key\n\t\t\t\t20171012164821_B49","doi-asserted-by":"crossref","unstructured":"Betriu C, Rodriguez-Avial I, Sanchez BA et al. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia (letter). J Antimicrob Chemother2002; 50:758\u20139.","DOI":"10.1093\/jac\/dkf196"},{"key":"key\n\t\t\t\t20171012164821_B50","doi-asserted-by":"crossref","unstructured":"Cercenado E, Cercenado S, Bouza E. In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob Agents Chemother2003; 47:2644\u20135.","DOI":"10.1128\/AAC.47.8.2644-2645.2003"},{"key":"key\n\t\t\t\t20171012164821_B51","unstructured":"Johnson B, Stevens T, Bouchillon S et al. In vitro study of tigecycline against 776 clinical isolates of non-Enterobacteriaceae from hospitals across Europe. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract 3311, p. 206. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B52","unstructured":"Johnson B, Stevens T, Bouchillon S et al. In vitro antibacterial activity of tigecycline a novel glycylcycline against clinical isolates of Enterobacteriaceae. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract 3464, p. 206\u2013207. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B53","doi-asserted-by":"crossref","unstructured":"Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents2000; 16:61\u20133.","DOI":"10.1016\/S0924-8579(00)00198-9"},{"key":"key\n\t\t\t\t20171012164821_B54","doi-asserted-by":"crossref","unstructured":"Wallace RJ Jr, Brown-Elliott BA, Crist CJ et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother2002; 46:3164\u20137.","DOI":"10.1128\/AAC.46.10.3164-3167.2002"},{"key":"key\n\t\t\t\t20171012164821_B55","doi-asserted-by":"crossref","unstructured":"Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis2002; 42:145\u20137.","DOI":"10.1016\/S0732-8893(01)00332-7"},{"key":"key\n\t\t\t\t20171012164821_B56","doi-asserted-by":"crossref","unstructured":"Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother2003; 47:665\u20139.","DOI":"10.1128\/AAC.47.2.665-669.2003"},{"key":"key\n\t\t\t\t20171012164821_B57","doi-asserted-by":"crossref","unstructured":"Dean CR, Visalli MA, Projan SJ et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother2003; 47:972\u20138.","DOI":"10.1128\/AAC.47.3.972-978.2003"},{"key":"key\n\t\t\t\t20171012164821_B58","doi-asserted-by":"crossref","unstructured":"Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001\u20132002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother2004; 53:1018\u201332.","DOI":"10.1093\/jac\/dkh232"},{"key":"key\n\t\t\t\t20171012164821_B59","doi-asserted-by":"crossref","unstructured":"Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis2004; 49:201\u20139.","DOI":"10.1016\/j.diagmicrobio.2004.03.002"},{"key":"key\n\t\t\t\t20171012164821_B60","doi-asserted-by":"crossref","unstructured":"Zhanel GG, Palatnick L, Nichol KA et al. Cross Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother2003; 47:1875\u201381.","DOI":"10.1128\/AAC.47.6.1875-1881.2003"},{"key":"key\n\t\t\t\t20171012164821_B61","unstructured":"Sader HS, Fritsche TR, Kirby JT et al. Activity of tigecycline tested against clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Neisseria meningitidis, a worldwide perspective. In: Programs and Abstracts of the European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004. Abstract 940, p. 247. Clin Microbiol Infect2004; 10 Suppl 3."},{"key":"key\n\t\t\t\t20171012164821_B62","unstructured":"Fritsche TR, Sader HS, Kirby JT et al. In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary staphylococci, streptococci and enterococci. Abstract P937. Clin Microbiol Infect2004; 10 Suppl 3: 246."},{"key":"key\n\t\t\t\t20171012164821_B63","doi-asserted-by":"crossref","unstructured":"Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother2003; 47:1867\u201374.","DOI":"10.1128\/AAC.47.6.1867-1874.2003"},{"key":"key\n\t\t\t\t20171012164821_B64","doi-asserted-by":"crossref","unstructured":"Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother2002; 46:2595\u2013601.","DOI":"10.1128\/AAC.46.8.2595-2601.2002"},{"key":"key\n\t\t\t\t20171012164821_B65","doi-asserted-by":"crossref","unstructured":"Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy2002; 22:1517\u201323.","DOI":"10.1592\/phco.22.17.1517.34117"},{"key":"key\n\t\t\t\t20171012164821_B66","unstructured":"Appelbaum PC, Kelly LM, Ednie LM et al. Comparative activities of dalbavancin against staphylococci, including a vancomycin-resistant strain of Staphylococcus aureus. In: Programs and Abstracts of the Forty-first Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2003. Abstract 173, p. 57. Infectious Diseases Society of America, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012164821_B67","unstructured":"Tedesco KL, Huang V, Rybak MJ. In vitro activities of daptomycin, arbekacin & tigecycline (GAR-936) against several clinical glycopeptide-intermediate Staphylococcus aureus (GISA) pathogens. In: Programs and Abstracts of the Forty-first Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2003. Abstract 179, p. 58. Infectious Diseases Society of America, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012164821_B68","doi-asserted-by":"crossref","unstructured":"Labthavikul P, Petersen PJ, Bradford PA. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother2003; 47:3967\u20139.","DOI":"10.1128\/AAC.47.12.3967-3969.2003"},{"key":"key\n\t\t\t\t20171012164821_B69","doi-asserted-by":"crossref","unstructured":"Jacobus NV, McDermott LA, Ruthazer R et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother2004; 48:1034\u20136.","DOI":"10.1128\/AAC.48.3.1034-1036.2004"},{"key":"key\n\t\t\t\t20171012164821_B70","doi-asserted-by":"crossref","unstructured":"Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin\u2013dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother2001; 45:2604\u20138.","DOI":"10.1128\/AAC.45.9.2604-2608.2001"},{"key":"key\n\t\t\t\t20171012164821_B71","unstructured":"Petersen PJ, Weiss WJ, Labthavikul P et al. The post-antibiotic effect and time\u2013kill kinetics of the glycylcyclines, GAR-936 (TBG-MINO) and (PAM-MINO). In: Programs and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-132, p. 266. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B72","doi-asserted-by":"crossref","unstructured":"Lefort A, Lafaurie M, Massias L et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother2003; 47:216\u201322.","DOI":"10.1128\/AAC.47.1.216-222.2003"},{"key":"key\n\t\t\t\t20171012164821_B73","doi-asserted-by":"crossref","unstructured":"Murphy TM, Deitz JM, Petersen PJ et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother2000; 44:3022\u20137.","DOI":"10.1128\/AAC.44.11.3022-3027.2000"},{"key":"key\n\t\t\t\t20171012164821_B74","doi-asserted-by":"crossref","unstructured":"Nannini EC, Pai SR, Singh KV et al. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother2003; 47:529\u201332.","DOI":"10.1128\/AAC.47.2.529-532.2003"},{"key":"key\n\t\t\t\t20171012164821_B75","doi-asserted-by":"crossref","unstructured":"Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother2003; 47:533\u201340.","DOI":"10.1128\/AAC.47.2.533-540.2003"},{"key":"key\n\t\t\t\t20171012164821_B76","unstructured":"Yin L, Lazzarini L, Bortolo S et al. Comparative evaluation of tigecycline and vancomycin in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis. In: Programs and Abstracts of the Forty-first Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2003. Abstract 180, p. 59. Infectious Diseases Society of America, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171012164821_B77","unstructured":"Mikels SM, Brown AS, Breden L et al. In vivo activities of GAR-936 (GAR), gentamicin (GEN), piperacillin (PIP), alone and in combination in a murine model of Pseudomonas aeruginosa pneumonia. In: Programs and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 414, p. 26. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B78","unstructured":"Fang GD, Weiss WJ, Scheld WM. Comparative efficacy of GAR-936 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits. In: Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 868, p. 51. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B79","unstructured":"Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. In: Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1403, p. 22. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B80","unstructured":"Muralidharan G, Mojaverian P, Micalizzi M et al. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In: Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 502, p. 17. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B81","unstructured":"Muralidharan G, Getsy J, Mayer P et al. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycycline antibiotic, in healthy subjects. In: Programs and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 416, p. 303. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B82","unstructured":"Troy SM, Muralidharan G, Micalizzi M et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-43, p. 5. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B83","unstructured":"Meagher AK, Cirincione BB, Liolios KA et al. Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment. Abstract P1023. Clin Microbiol Infect2004; 10 Suppl 3: 274."},{"key":"key\n\t\t\t\t20171012164821_B84","unstructured":"Huang V, Brown WJ, Rybak MJ. Evaluation of tigecycline, linezolid, quinupristin\u2013dalfopristin, arbekacin, and daptomycin alone and in combination against two clinical strains of vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Abstract P1040. Clin Microbiol Infect2004; 10 Suppl 3: 279\u201380."},{"key":"key\n\t\t\t\t20171012164821_B85","unstructured":"Ellis-Grosse EJ, Loh E. Tigecycline is safe and effective in the treatment of skin and skin structure infections: results of two double-blind Phase 3 comparison studies with vancomycin\/aztreonam. In: Programs and Abstracts of the 9th Western Pacific Congress on Chemotherapy and Infectious Diseases, Bangkok, Thailand, 2004. Abstract FP-C-6, p. 219. Thailand Infectious Diseases Society."},{"key":"key\n\t\t\t\t20171012164821_B86","unstructured":"Dartois N. Results of a Phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin\/aztreonam to treat complicated skin and skin structure infections. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract L-986, p. 389. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171012164821_B87","unstructured":"Dartois N, Gioud-Paquet M, Ellis-Grosse EJ et al. Tigecycline vs imipenem\/cilastatin for treatment of complicated intra-abdominal infections. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract LB-992c, p. 12. American Society for Microbiology, Washington, DC, USA."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/3\/470\/2029972\/dki248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T16:19:09Z","timestamp":1683130749000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/3\/470\/690966\/Tigecycline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,22]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,7,22]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki248","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,9]]},"published":{"date-parts":[[2005,7,22]]}}}